Early Screening for Multiple Myeloma Based on Liquid Biopsy cfDNA Fragmentomics

Study on Early Screening of Myeloma Based on Liquid Biopsy cfDNA Fragmentomics Technology. This study aims to construct and validate a set of machine learning models for the early screening of myeloma tailored to the Chinese population, based on plasma cfDNA fragmentomics features, to effectively distinguish myeloma patients from healthy individuals.

NCT Number	NCT07684274
Lead Sponsor	The First Affiliated Hospital with Nanjing Medical University Collaborators: Nanjing Geneseeq Technology Inc.
Conditions	Multiple Myeloma (MM), Smoldering Multiple Myeloma (SMM), MGUS
Enrollment	290 participants
Start Date	2026-06-13
Primary Completion	2027-07-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-06